Invesco’s Black Diamond Therapeutics BDTX Stock Holding History

Invesco’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$244K	Buy	131,663 +24,263	+23%	+$59.3K	﹤0.01%	3516
2026 Q1	$229K	Sell	107,400 -24,038	-18%	-$57.2K	﹤0.01%	3439
2025 Q4	$319K	Buy	131,438 +36,094	+38%	+$128K	﹤0.01%	3357
2025 Q3	$361K	Buy	95,344 +35,134	+58%	+$103K	﹤0.01%	3354
2025 Q2	$149K	Buy	60,210 +14,221	+31%	+$27.4K	﹤0.01%	3586
2025 Q1	$71.3K	Buy	45,989 +27,777	+153%	+$58.2K	﹤0.01%	3670
2024 Q4	$39K	Buy	18,212 +732	+4%	+$2.1K	﹤0.01%	3713
2024 Q3	$76K	Sell	17,480 -694,902	-98%	-$3.78M	﹤0.01%	3651
2024 Q2	$3.32M	Buy	+712,382	New	+$3.82M	﹤0.01%	2377
2021 Q4	–	Sell	-10,633	Closed	-$90K	–	4031
2021 Q3	$90K	Buy	+10,633	New	+$105K	﹤0.01%	3953

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Invesco's BDTX Position: Q2 2026 in Review

Invesco increased its Black Diamond Therapeutics (BDTX) stake by 23% in Q2 2026, buying an estimated $59.3K and bringing the position to 131,663 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #3516.

Invesco first reported a position in BDTX in Q3 2021 and has held it in 10 quarters since. The position peaked at $3.32M in Q2 2024. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

Invesco held 131,663 shares of Black Diamond Therapeutics worth $244K as of Q2 2026.
Invesco bought 24,263 Black Diamond Therapeutics shares in Q2 2026, an estimated $59.3K.
Black Diamond Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3516 holding.
Invesco first reported a position in Black Diamond Therapeutics in Q3 2021 and has held it in 10 quarters since.
Invesco's Black Diamond Therapeutics position peaked at $3.32M in Q2 2024.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.